Apheresis vs Leukapheresis: How the Procedures Differ

Apheresis is the umbrella term for any procedure that draws blood, separates it into its individual components, removes a targeted component, and returns the rest to the person’s bloodstream. Leukapheresis is one specific type of apheresis, the type that targets white blood cells. The relationship is straightforward: every leukapheresis is an apheresis procedure, but not every apheresis procedure is a leukapheresis. The distinction matters because the clinical reasons for collecting white blood cells, the equipment settings involved, and the risks to the patient or donor differ in meaningful ways from other apheresis subtypes like plasma or platelet collection.

How Apheresis Works as a Category

The core idea behind all apheresis is selective removal. Whole blood is drawn from a vein, run through a machine that spins or filters it to separate the components, and then the parts you do not want to collect are returned to the person. The word itself comes from the Greek for “to take away.”¹ What changes from one subtype to the next is which component you are taking away. The naming convention is literal: attach the target component’s name to “-pheresis” or “-apheresis,” and you have the procedure name.

The most common subtypes include:

Plasmapheresis: removes plasma, the liquid portion of blood. Used therapeutically for autoimmune conditions and in plasma donation.
Plateletpheresis: removes platelets. Used heavily in blood banking to collect single-donor platelet units.
Leukapheresis: removes white blood cells (leukocytes). Used both therapeutically and as a harvesting step for transplant or cell therapy.
Erythrocytapheresis: removes red blood cells. Used in conditions like sickle cell disease to exchange abnormal red cells for healthy ones.

All of these run on similar centrifugal cell-separator machines, but the spin speeds, collection times, and anticoagulant doses are adjusted depending on which blood layer you are trying to pull off.²

What Makes Leukapheresis Different in Practice

Leukapheresis specifically separates and collects the white-blood-cell-rich layer from peripheral blood. Because white blood cells sit in a narrow band between red cells and plasma when blood is spun, collecting them cleanly is trickier than collecting plasma or platelets alone. The procedure often takes longer per session and typically processes a larger volume of blood. The collected product, sometimes called a “leukapheresis product” or “leukopak,” contains a concentrated mixture of white blood cells, though the exact composition varies depending on the patient’s blood counts and the machine settings used.

Another practical difference is why leukapheresis is performed. Plateletpheresis and plasmapheresis are routine operations at blood banks, performed on healthy donors millions of times a year. Leukapheresis is comparatively uncommon and is almost always done in a hospital or specialized apheresis center, either as a therapeutic intervention for a sick patient or as a collection step for advanced therapies like stem cell transplant or CAR-T cell manufacturing.³ This lower frequency means that leukapheresis-specific risks have been studied less extensively than the risks of platelet or plasma collection.

Therapeutic Leukapheresis for Dangerously High White Cell Counts

One of the oldest and most direct uses of leukapheresis is as an emergency treatment for hyperleukocytosis, a condition where the white blood cell count climbs to dangerously high levels. This typically happens in acute leukemias, where malignant white cells multiply explosively and can clog small blood vessels in the lungs and brain, causing life-threatening complications. The idea is simple: pull out the excess white cells mechanically while chemotherapy gets started.

A pediatric case report documented an 81% reduction in white cell count from a single leukapheresis session in a child with acute myeloid leukemia, with no adverse events from the procedure itself.⁴ Results like that sound impressive, but the broader evidence is more complicated. A systematic review and meta-analysis pooling data from multiple studies found that leukapheresis did not produce a statistically significant reduction in early death for patients with acute myeloid leukemia and hyperleukocytosis. The pooled estimate showed only a modest trend toward benefit that could easily have been due to chance.⁵

This disconnect between dramatic individual responses and lukewarm population-level data is a persistent tension in the field. Most hematologists still consider therapeutic leukapheresis a reasonable bridge therapy while chemotherapy takes effect, especially when the white count is extremely high and symptoms suggest the blood is “sludging” in small vessels. But the evidence is not strong enough to call it a proven life-saver in a statistical sense. The American Society for Apheresis maintains fact sheets and categorized indications for dozens of conditions, including hyperleukocytosis, using evidence-based grading to guide when apheresis is and is not recommended.⁶

Stem Cell Collection Through Leukapheresis

Outside of emergency therapy, the most established use of leukapheresis is harvesting peripheral blood stem cells for transplantation. Before a bone marrow transplant, patients or healthy donors are given a drug, most commonly granulocyte colony-stimulating factor (G-CSF), that coaxes stem cells out of the bone marrow and into circulating blood.⁷ Once those stem cells are circulating, leukapheresis collects them. The target cells (CD34-positive stem cells) ride along with the white blood cell layer, so the leukapheresis machine is set to collect that entire layer, and the stem cells are identified and counted from the product afterward.

Timing matters a great deal. Stem cell counts in the blood peak a few days after G-CSF mobilization begins, and collecting too early or too late means a poor yield. Researchers have shown that measuring the CD34-positive cell concentration in the blood the day before a planned collection can predict the yield from the leukapheresis itself, helping clinicians decide whether to proceed or wait another day.⁸ In healthy donors, the pre-collection blood count is similarly the strongest predictor of how many stem cells the leukapheresis will capture.⁹

This is distinct from a standard bone marrow harvest, which involves needle aspiration directly from the hip bone under anesthesia. Peripheral blood stem cell collection via leukapheresis has largely replaced bone marrow harvest for many transplant types because it avoids general anesthesia and yields cells that engraft faster. But the two approaches are not identical in outcomes or donor experience, and the choice between them depends on clinical factors specific to each case.

Leukapheresis as the Starting Point for CAR-T Cell Therapy

A newer and rapidly growing use of leukapheresis is collecting the raw material for chimeric antigen receptor T-cell (CAR-T) therapy, one of the most promising developments in cancer treatment over the past decade. In CAR-T therapy, a patient’s own T cells are collected, genetically engineered in a lab to recognize and attack cancer cells, expanded to large numbers, and then infused back. The very first step in that chain is leukapheresis: you need to get the patient’s T cells out of their blood.¹⁰

The quality of the leukapheresis product turns out to be a critical determinant of whether the whole CAR-T manufacturing process succeeds. If the collected product contains too few T cells, or too many contaminating cells like monocytes, the manufacturing can fail or produce a suboptimal product. A patient’s pre-collection blood lymphocyte count strongly correlates with the T-cell content of the leukapheresis product.¹¹ This creates challenges for patients with lymphoma or leukemia, who often have depressed lymphocyte counts from prior rounds of chemotherapy.

Manufacturing techniques have evolved to deal with these constraints. Research has shown that concentrating the leukapheresis product before freezing it can reduce the collection volume dramatically while actually improving purity. One study found that the volume was reduced roughly fivefold while the proportion of non-target cells like monocytes and platelets dropped, giving the manufacturing lab a cleaner starting material.¹² As CAR-T therapy expands to treat more cancer types, leukapheresis optimization has become its own subspecialty within transfusion medicine.¹³

Complications and How They Compare Across Apheresis Types

All apheresis procedures share a common set of potential side effects, but the frequency and severity vary by subtype. The most universal issue is citrate toxicity. Citrate is the anticoagulant used to keep blood from clotting inside the machine, and as it is returned to the body it temporarily binds calcium in the bloodstream. The result can be tingling around the lips and fingers, muscle cramps, and in rare cases more serious drops in ionized calcium. These symptoms are usually managed by slowing the return rate or giving oral or intravenous calcium supplements.¹⁴

One study that tracked adverse events across different therapeutic apheresis types found that leukapheresis had a reaction rate of about 6%, which sits between the higher rate seen with red cell exchange (around 10%) and the lower rate seen with autologous stem cell collection (under 2%).¹⁵ A broader review of leukapheresis safety concluded that the overall track record is reassuring, with most problems involving venous access difficulties, vasovagal episodes (feeling faint), or citrate symptoms that respond quickly to simple interventions.¹⁶

Leukapheresis does have some risk factors that platelet or plasma apheresis do not share to the same degree. The procedure often processes a larger total blood volume, which means more citrate exposure over a longer session. Patients undergoing therapeutic leukapheresis for leukemia are often medically fragile, with abnormal organ function that can make them more sensitive to fluid shifts and electrolyte changes. Patients with multiple myeloma, for instance, appear to be more prone to citrate reactions during leukapheresis than patients with other cancers, though the exact mechanism for this increased sensitivity is unclear.¹⁷

Vascular Access and Practical Logistics

Getting adequate blood flow is a practical challenge for any apheresis procedure, and it is especially relevant for leukapheresis because of the large volumes processed. You need blood to flow out of one site, through the machine, and back in through either the same line (in a single-needle setup) or a second site (dual-needle). For healthy stem cell donors and many patients, peripheral veins in the arms work fine. A study of 114 patients undergoing stem cell collection found that about 57% could use peripheral veins successfully, while the remaining 43% needed a temporary central venous catheter placed in a larger vein, usually in the neck or chest.¹⁸ Men were more likely than women to have adequate peripheral veins, and patients with certain diagnoses fared better than others.

For routine plateletpheresis in a blood bank, vascular access is rarely a concern because most donors are healthy adults with good veins. But patients coming in for therapeutic leukapheresis may have veins damaged by prior chemotherapy, poor nutrition, or dehydration. Planning for vascular access is therefore a bigger part of the logistical conversation before leukapheresis than before a routine platelet donation.

Leukapheresis in Children

Performing leukapheresis on small children introduces unique challenges. The machines are designed for adults, and a young child’s total blood volume may be a fraction of the tubing and centrifuge volume of the device. This means that at any given moment during the procedure, a significant portion of the child’s blood is outside the body, which can cause dangerous drops in blood pressure or hemoglobin if not carefully managed.

Anticoagulation strategy also differs. One institution’s experience with children weighing 30 kilograms or less found that different anticoagulant regimens evolved over time, moving from heparin-based approaches to citrate-based ones supplemented with intravenous calcium and magnesium to prevent the electrolyte disturbances that citrate causes.¹⁹ Pediatric leukapheresis often requires a blood prime, where donor red cells are used to fill the machine’s tubing before connecting the child, to avoid depleting their circulating blood volume. These considerations are less of a concern for plateletpheresis in adults but become critical in pediatric leukapheresis.

Photopheresis, a Specialized Offshoot

Extracorporeal photopheresis (ECP) is a procedure that starts with leukapheresis and then adds a twist: the collected white blood cells are treated with a light-sensitizing drug and exposed to ultraviolet light before being returned to the patient. This combination modifies the immune cells in ways that can quiet down overactive immune responses. ECP is used to treat graft-versus-host disease, a complication of bone marrow transplant where donor immune cells attack the recipient’s body, as well as certain types of cutaneous T-cell lymphoma.²⁰ Photopheresis is technically a leukapheresis-based procedure, but it is usually discussed as its own category because the therapeutic action comes from the UV treatment of the cells, not simply from removing them.

The Donor Experience

For healthy individuals who undergo leukapheresis as stem cell donors, the experience is different from what most people imagine when they hear “bone marrow donation.” There is no surgery and no general anesthesia. The donor sits in a chair, typically for several hours, while blood circulates through the machine. Most donors receive G-CSF injections for a few days beforehand, which can cause bone pain, headaches, and fatigue as the drug stimulates the marrow.

A randomized study comparing the experience of sibling donors who underwent either bone marrow harvest or peripheral blood stem cell collection found that neither procedure was pain-free. Anxiety levels before the collection were high in both groups, and donors undergoing the blood cell collection (which involves leukapheresis) actually had significantly higher pre-procedure anxiety than those undergoing surgical bone marrow harvest.²¹ This may seem counterintuitive, since the leukapheresis approach avoids an operating room, but the unfamiliarity of being hooked to an apheresis machine for hours, combined with the days of G-CSF injections, creates its own kind of stress.

Quality Standards and the Regulatory Landscape

As leukapheresis has moved from a niche therapeutic procedure to the critical first step in manufacturing commercial cell therapies, the regulatory expectations around it have changed. A leukapheresis product destined for CAR-T manufacturing is now classified as starting material for a biological product, which brings it under different quality and documentation requirements than a routine apheresis collection at a blood bank. Recent analyses have pointed out that the quality standards applied to leukapheresis collections can differ depending on whether the product supports an early-phase clinical trial or a fully licensed commercial therapy.²²

Predictability of the collection is also becoming more important. Research has confirmed that the pre-collection white blood cell count, and specifically the mononuclear cell count, is the single strongest predictor of how many target cells the leukapheresis will yield.²³ For a blood bank collecting platelets, a low yield means the unit might not meet minimum standards. For a CAR-T manufacturer, a poor leukapheresis yield can mean a patient does not get their therapy at all. The stakes have raised the bar for how carefully leukapheresis is planned and executed, and have pushed transfusion medicine specialists to develop prediction models and optimization protocols that would have been unnecessary a generation ago.